CardiacSense Ltd

CardiacSense is a developer of a wearable technology for continuous cardiac arrhythmia detection and non-inflating blood pressure monitoring. CardiacSense is based in Caesarea, Israel.
Overview.
CardiacSense Ltd is a private limited company founded in 2009 as Sportracker. The company formerly developed a device for tracking heart rate readings during sports activities. In 2015 the company changed its name to CardiacSense and refocused activities on medical devices. CardiacSense's devices monitor heart rate for the purpose of detecting heart disorders such as atrial fibrillation tachycardia, bradycardia, PVCs, PACs, Pause, LQT and cardiac arrest. The device comes in the form of a wrist watch. It monitors heart rate (HR), heart rate variabilities (HRV), respiratory rate, blood pressure (continuously and cuff-less) as well as measures measures oxygen saturation (SpO2) and body temperature, skin temperature, and additional vital signs.
The watch can monitor and detect sleep apnea as well as Chronic Obstructive Pulmonary Disease (COPD) and Congestive Heart Failure (CHF) patients’ health deterioration.
Technology.
CardiacSense technology combines Electrocardiogram (ECG) and Photoplethysmography (PPG) sensors along with a unique mechanics, and algorithm. The PPG is an optical sensing technique that measures changes in fluid (blood) volume. The company developed a proprietary optical solution as well as an artifact sensor that improve the accuracy by eliminating movement artifacts in PPG sensor. The device has a continuous monitoring capacity of over a year. In case of Arrhythmia, such as Atrial Fibrillation, the watch alerts the user and send messages to the patient's physician. The user's data is saved in the watch memory and uploaded to a cloud application via the user's cellular device.
In the United States, the watch will be issued by prescription and the physician can choose if and when to be notified.
In Europe and rest of the world, the watch will not require prescription.
CardiacSense completed its first clinical trial at the Tel Aviv Sourasky Medical Center in 2016. Since then CardiacSense completed different multi-site clinical trials at the Tel Aviv Sourasky Medical Center, The Rambam Healthcare Campus in Haifa and The Sheba Medical Center in Ramat Gan. The company is planning a series of new clinical trials in Israel and in the United States for respiratory rate, sleep apnea, oxygen saturation and blood pressure.
Capitalization.
CardiacSense has raised approximately $3.6 million through angel investors and one public company up to 2017 and an additional $5.0 million in 2018–2019.
The company did additional fundraising of $9.0 million from April 2019 to February 2021, bringing the total raised to $17.7 million by February 2021.
Regulatory.
Cardiacsense Medical Watch has CE Mark for continuous HR, HRV, Atrial Fibrillation. detection and spot one lead ECG. FDA clearance is in process.